RAPID MICRO BIOSYSTEMS, INC. 8-K

What Happened

• Rapid Micro Biosystems, Inc. (filed 8-K on May 19, 2026) entered an Underwriting Agreement (May 18, 2026) with TD Securities (USA) LLC and Lake Street Capital Markets LLC for an underwritten offering expected to close May 20, 2026. The offering includes 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu) sold together with Series A and Series B common stock warrants, plus up to 1,463,000 pre-funded warrants sold in lieu of shares for certain investors. The company estimates net proceeds of approximately $8.9 million to be used for working capital and general corporate purposes.
• The company also entered a Securities Purchase Agreement (May 18, 2026) with certain directors and officers to sell 71,607 shares and accompanying Series A and Series B warrants in a concurrent registered direct offering for gross proceeds of about $140,000; that concurrent sale is contingent on the closing of the public offering.

Key Details

• Offered securities: 3,581,000 shares + accompanying Series A and Series B warrants; up to 1,463,000 pre-funded warrants in lieu of shares for some investors.
• Pricing: each share + Series A & B warrants combined priced at $1.955; each pre-funded warrant + Series A & B warrants combined priced at $1.945. Pre-funded warrants have $0.01 exercise price.
• Warrant terms: Series A warrants exercisable after 6 months and expire 1 year after issuance; Series B warrants exercisable after 6 months and expire 5 years after issuance.
• Holder limits and rights: exercise limited by beneficial ownership caps (e.g., 4.5% / 4.99% / 9.99% options, adjustable up to 19.99% with notice); Series B warrants include 12-month participation rights in future offerings up to 25% pro rata.
• Use of proceeds: net proceeds ~ $8.9M for working capital and general corporate purposes; D&O concurrent offering proceeds ~ $140K.

Why It Matters

• This transaction raises immediate capital (~$8.9M net) to fund operations, which can help liquidity but will dilute existing shareholders if warrants and pre-funded warrants are exercised.
• The warrants have staggered expirations and ownership caps that limit immediate concentration of shares but allow for future dilution over time.
• Insider participation (directors and officers buying in the concurrent offering) may signal support, though the D&O purchase is relatively small (~$140K) compared with the overall raise.
• Investors should note the close is expected May 20, 2026 and is subject to customary closing conditions; details and full terms are in the filed underwriting and purchase agreements.